

NOTE: This order is nonprecedential.

**United States Court of Appeals
for the Federal Circuit**

**IN RE CYCLOBENZAPRINE HYDROCHLORIDE
EXTENDED-RELEASE CAPSULE PATENT
LITIGATION**

**EURAND, INC. (NOW KNOWN AS APTALIS
PHARMATECH, INC.), CEPHALON, INC.,
AND ANESTA AG,
*Plaintiffs- Appellees,***

v.

**IMPAX LABORATORIES, INC.,
*Defendant-Appellant,***

AND

**MYLAN INC. AND MYLAN PHARMACEUTICALS
INC.,
*Defendants-Appellees,***

AND

**PAR PHARMACEUTICAL INC., AND TWI
PHARMACEUTICALS INC.,
*Defendants.***

2012-1280

Appeal from the United States District Court for the District of Delaware in case no. 09-MD-2118, Judge Sue L. Robinson.

ON MOTION

O R D E R

Mylan Inc. et al. (Mylan) move to reform the caption. Eurand, Inc. et al. oppose.

The clerk's office reformed the caption on April 17 to reflect that Mylan is an appellee. As an appellee, Mylan may make arguments in support of the ruling on review. Disputes concerning Mylan's possible arguments on the merits may be raised in the briefs, if appropriate.

Upon consideration thereof,

IT IS ORDERED THAT:

The motion is moot.

FOR THE COURT

MAY 03 2012

Date

/s/ Jan Horbaly

Jan Horbaly
Clerk

cc: Debra J. McComas, Esq.
John R. Lane, Esq.
James W. Wallace, Jr., Esq.

s19

FILED
U.S. COURT OF APPEALS FOR
THE FEDERAL CIRCUIT

MAY 03 2012

JAN HORBALY
CLERK